

Anke C Reinacher-Schick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9844858/publications.pdf>

Version: 2024-02-01

55
papers

979
citations

687363

13
h-index

454955

30
g-index

61
all docs

61
docs citations

61
times ranked

1435
citing authors

#	ARTICLE	IF	CITATIONS
1	Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). <i>Journal of Clinical Oncology</i> , 2022, 40, 72-82.	1.6	42
2	Low Serological Prevalence of SARS-CoV-2 Antibodies in Cancer Patients at a German University Oncology Center. <i>Oncology Research and Treatment</i> , 2022, 45, 112-117.	1.2	7
3	Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy. <i>Cancers</i> , 2022, 14, 526.	3.7	1
4	Negative hyperselection for mutations associated with anti-EGFR antibody resistance in <i>RAS</i> wildtype metastatic colorectal cancer (mCRC): Evaluation of the PANAMA trial (AIO-KRK-0212). <i>Journal of Clinical Oncology</i> , 2022, 40, 3536-3536.	1.6	2
5	Label-free and automated approach to rapidly classify microsatellite instability (MSI) in early colon cancer (CC) analyzing the AIO ColoPredictPlus 2.0 (CPP) registry trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3616-3616.	1.6	0
6	BRAF-mutant metastatic colorectal cancer: Prognostic and predictive value of primary tumor location—A pooled analysis of the AIO studies FIRE-1, CIOX, XELAVIRI, FIRE-3, and VOLFI.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3576-3576.	1.6	2
7	A phase 2 multicenter, open-label, randomized, controlled trial in patients with stage II/III colorectal cancer who are ctDNA positive following resection to compare efficacy of autogene cevumeran versus watchful waiting.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS3641-TPS3641.	1.6	3
8	Attitude towards and experience with SARS-CoV-2 vaccination among German cancer patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18603-e18603.	1.6	0
9	Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Updated final results of the randomized phase II AIO-NEONAX trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4133-4133.	1.6	8
10	Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4008-4008.	1.6	39
11	Impact of age and gender on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in <i>RAS</i> WT metastatic colorectal cancer (mCRC): Subgroup analysis of the PANAMA-study (AIO-KRK-0212).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3567-3567.	1.6	0
12	Geriatric assessment (GA) and the influence on the variability of treatment recommendations for elderly patients (pts) with gastrointestinal (GI) tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12049-12049.	1.6	0
13	Impact of the COVID-19 pandemic on colorectal cancer (CRC) care: Data from 22 German cancer centers (CC) and the Institute of Pathology, Ruhr-University Bochum - the AIO (Working Group for Internal) <i>Journal of Clinical Oncology</i> , 2022, 40, 3626-3626.	1.6	0
14	Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of panitumumab (Pmab), fluorouracil and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab-FOLFOX induction in <i>RAS</i> wildtype metastatic colorectal cancer (mCRC): PANAMA trial (AIO-KRK-0212).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3537-3537.	1.6	0
15	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3929-3939.	1.6	66
16	POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 412-412.	1.6	1
17	Dose-dependent immunomodulatory effects of bortezomib in experimental autoimmune neuritis. <i>Brain Communications</i> , 2021, 3, fcab238.	3.3	4
18	Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 811291.	2.3	2

#	ARTICLE	IF	CITATIONS
19	Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial. <i>Clinical Chemistry</i> , 2020, 66, 1510-1520.	3.2	11
20	Label-free, automated classification of microsatellite status in colorectal cancer by infrared imaging. <i>Scientific Reports</i> , 2020, 10, 10161.	3.3	13
21	Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 648-648.	1.6	3
22	POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e16800-e16800.	1.6	0
23	Implementing a novel method to estimate the "Burden of Therapy" (BOTH) for patients with metastatic pancreatic cancer treated with gemcitabine plus afatinib vs. gemcitabine in the AIO ACCEPT trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16786-e16786.	1.6	0
24	Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 686-686.	1.6	0
25	Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P).. <i>Journal of Clinical Oncology</i> , 2020, 38, 750-750.	1.6	1
26	FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). <i>Journal of Clinical Oncology</i> , 2019, 37, 3401-3411.	1.6	132
27	Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer. <i>Visceral Medicine</i> , 2019, 35, 387-391.	1.3	10
28	Prospective Study of the Clinical, Electrophysiologic, and Sonographic Characteristics of Oxaliplatin-Induced Neuropathy. <i>Journal of Neuroimaging</i> , 2019, 29, 133-139.	2.0	11
29	Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3511-3511.	1.6	6
30	NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AIO pancreatic cancer group (AIO-PAK-0313) Safety interim analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4128-4128.	1.6	8
31	Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA4-LBA4.	1.6	11
32	A blood-based assay for diagnosis of early-stage pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 234-234.	1.6	0
33	Tumor dynamics with fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFI A randomized, open label, phase-2 study (AIO) Tj ETQq1 1 0.784314 rgBT /Over	1.6	8
34	Correlation of histopathologic regression with progression free survival (PFS) in patients (pts) with RAS wildtype metastatic colorectal cancer (mCRC) under fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone: Subgroup analysis of VOLFI (AIO-KRK-0109).. <i>Journal of Clinical Oncology</i> , 2019, 37, e15024-e15024.	1.6	0
35	What does physicians' clinical expertise contribute to oncologic decision-making? A qualitative interview study. <i>Journal of Evaluation in Clinical Practice</i> , 2018, 24, 180-186.	1.8	12
36	FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, E9-E12.	1.4	16

#	ARTICLE	IF	CITATIONS
37	Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial. <i>Frontiers in Oncology</i> , 2018, 8, 474.	2.8	13
38	Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. <i>European Journal of Cancer</i> , 2018, 101, 105-113.	2.8	19
39	mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC): A randomized phase II VOLFI trial of the AIO (AIO- KRK0109).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3509-3509.	1.6	14
40	Serial analysis of mutant KRAS in circulation cell-free DNA (cfDNA) of patients with KRAS mutant metastatic colorectal cancer: A translational study of the KRK0207 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15599-e15599.	1.6	2
41	Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. <i>Molecular Oncology</i> , 2017, 11, 208-219.	4.6	125
42	Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience. <i>Therapeutic Advances in Neurological Disorders</i> , 2017, 10, 339-341.	3.5	34
43	Severe refractory CIDP: a case series of 10 patients treated with bortezomib. <i>Journal of Neurology</i> , 2017, 264, 2010-2020.	3.6	33
44	Localization of the primary tumor (LPT) and maintenance strategies after first line oxaliplatin (Ox), fluoropyrimidine (FP), and bevacizumab (Bev) in metastatic colorectal cancer (mCRC): Results from the AIO 0207 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3543-3543.	1.6	4
45	Association of high microsatellite instability (MSI-H) with a high immunoscore (IS) compared to PD-L1 expression and increased survival in patients (pts) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (Ox) and fluoropyrimidine (FP): A pooled analysis of the AIO KRK 0207 and RO91 trials.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3595-3595.	1.6	1
46	Efficacy of gemcitabine with erlotinib in rash-positive patients selected according to eligibility for FOLFIRINOX.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4108-4108.	1.6	1
47	Association of microsatellite instability with distinct clinical and molecular characteristics in resected colon cancer: Analysis of a platform trial of the AIO colorectal study group—Colopredict Plus.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15086-e15086.	1.6	2
48	Amphiphysin-positive paraneoplastic myelitis and stiff-person syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e285.	6.0	19
49	POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCA).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4152-TPS4152.	1.6	15
50	Influence of KRAS exon 2 mutation variants as well as NRAS- and BRAF-mutations on outcome of patients with metastatic colorectal cancer (mCRC) receiving combination chemotherapy with or without bevacizumab.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3551-3551.	1.6	0
51	Multiple cerebral infarctions in a young patient with heroin-induced hypereosinophilic syndrome. <i>Journal of the Neurological Sciences</i> , 2015, 356, 193-195.	0.6	14
52	Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1355-1369.	10.7	228
53	ACCEPT: Afatinib as cancer therapy for exocrine pancreatic tumors—An explorative randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4150-TPS4150.	1.6	2
54	Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3503-3503.	1.6	17

#	ARTICLE	IF	CITATIONS
55	Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated <i>ERBB2</i> -Positive Esophagogastric Adenocarcinoma. JAMA Oncology, 0, , .	7.1	17